Investor Presentaiton

FY 2023: Financial Highlights FY 2023 Revenue (€ Million) 984 Non HVS HVS +10% 93 Base business Covid-19 headwind 1.085 366 (34%) +25% 11% revenue growth on a CC basis driven by growth in both segments, higher volumes and the mix shift to high value solutions. ● Record revenue from HVS, representing 34% of total revenue Excluding Covid-19 (estimated to be ~2% of total revenue), revenue grew 22% yoy Gross profit margin decline due to lower EZ-FillⓇ vial volumes, temporary inefficiencies tied to start-up, higher depreciation, FX, and short-term underutilization on some vial lines 293 (30%) FY 2022 FY 2023 Margins Gross Profit Margin Operating Profit Margin SG, Stevanato Group FY 2023 Operating profit decrease due to lower gross profit and other income On the bottom line: • Net profit of € 145.7M (+2% yoy), or € 0.55 of diluted EPS Adjusted net profit¹ of € 154.7M (+5% yoy), or € 0.58 of adjusted diluted EPS¹ FY 2023 FY 2022 31.3% 32.5% 18.5% 19.6% Adjusted EBITDA¹ of € 291.5M (+11% yoy); adjusted EBITDA margin¹ of 26.9% (+10 bps yoy) ¹Adjusted operating profit margin, adjusted net profit, adjusted DEPS, adjusted EBITDA and adjusted EBITDA margin, Net Debt, CapEx, Free Cash Flow are non-GAAP financial measures. Please refer to slides 37 to 46 for a reconciliation of non-GAAP measures. Stevanato Group Investor Presentation, March 2024 21

View entire presentation